Patents by Inventor Michael E. Garst

Michael E. Garst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclosporin analogs
    Patent number: 9561259
    Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: February 7, 2017
    Assignee: Allergan, Inc.
    Inventors: Michael E. Garst, William Robert Carling, David Arthur Scowen, Michael E. Stern, Christopher S Schaumburg
  • CYCLOSPORIN ANALOGS
    Publication number: 20170029469
    Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
    Type: Application
    Filed: October 11, 2016
    Publication date: February 2, 2017
    Inventors: Catherine Simone Victoire Frydrych, William Robert Carling, Michael E. Garst, Michael E. Stern, Christopher S. Schaumburg
  • Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators
    Patent number: 9550746
    Abstract: The present invention relates to novel benzofuran-2-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: January 24, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Benzimidazole derivatives as selective blockers of persistent sodium current
    Patent number: 9540332
    Abstract: The present invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof; wherein R, R1, R2, R3, R4, m, and n are as defined herein, to pharmaceutical compositions comprising said compound, and to methods of treating diseases or conditions mediated by elevated persistent sodium current, such as an ocular disorder, multiple sclerosis, seizure disorder, and chronic pain.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: January 10, 2017
    Assignee: ALLERGAN, INC.
    Inventors: George R. Ehring, Ellen Chao, Herman Ng, Hau Ton, Jia Chian Li, Joseph S. Adorante, Michael E. Garst, Howard B. Rind, Mark R. Hansen, Alfred Arthur Avey, Jr., Lloyd Jay Dolby, Shervin Esfandiari, Vivian R. MacKenzie, Jeremiah Andrew Marsden, David Charles Muchmore
  • BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT
    Publication number: 20160355485
    Abstract: The present invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof; wherein R, R1, R2, R3, R4, m, and n are as defined herein, to pharmaceutical compositions comprising said compound, and to methods of treating diseases or conditions mediated by elevated persistent sodium current, such as an ocular disorder, multiple sclerosis, seizure disorder, and chronic pain.
    Type: Application
    Filed: September 24, 2014
    Publication date: December 8, 2016
    Inventors: George R. Ehring, Ellen Chao, Herman Ng, Hau Ton, Jia Chian Li, Joseph S. Adorante, Michael E. Garst, Howard B. Rind, Mark R. Hansen, Alfred Arthur Avey, JR., Lloyd Jay Dolby, Shervin Esfandiari, Vivian R. MacKenzie, Jeremiah Andrew Marsden, David Charles Muchmore
  • ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS
    Publication number: 20160354346
    Abstract: The present invention relates to method for treating skin diseases and skin conditions in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, or enantiomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Application
    Filed: August 18, 2016
    Publication date: December 8, 2016
    Inventors: Mohammed I. Dibas, Daniel W. Gil, John E. Donello, Ken Chow, Liming Wang, Michael E. Garst
  • 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-UREA DERIVATIVES AS FORMYL PEPTIDE MODULATORS
    Publication number: 20160340318
    Abstract: The present invention relates to 1-(2,5-dioxoimidazolidin-1-y)-3-substituted urea compounds, processes for preparing them, pharmaceutical compositions containing them, their use as pharmaceuticals as modulators of the FPR2 receptor, and to methods of treating inflammatory diseases or conditions in a subject in need thereof by administering the compound(s) or pharmaceutical composition to the subject.
    Type: Application
    Filed: January 27, 2015
    Publication date: November 24, 2016
    Inventors: Richard L. Beard, Vidyasagar Vuligonda, Thong Huy Vu, Michael E. Garst
  • Substituted cyclopentanes for inducing hair growth
    Patent number: 9499478
    Abstract: Provided herein, inter alia, are, methods of using esters of bimatoprost with the Formula (I):
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: November 22, 2016
    Assignee: ALLERGAN, INC.
    Inventors: David F. Woodward, Jenny W. Wang, Neil J. Poloso, Todd S. Gac, Robert M. Burk, Michael E. Garst
  • UREA HYDANTOIN DERIVATIVES AS FORMYL PEPTIDE MODULATORS
    Publication number: 20160332972
    Abstract: The present invention relates to urea hydantoin compounds, processes for preparing them, pharmaceutical compositions containing them, and their use as pharmaceuticals as modulators of the FPR2 receptor, and to methods of treating inflammatory diseases or conditions in a subject in need thereof by administering the compound(s) or pharmaceutical composition to the subject.
    Type: Application
    Filed: January 27, 2015
    Publication date: November 17, 2016
    Inventors: Richard L. Beard, Vidyasagar Vuligonda, Thong Huy Vu, Michael E. Garst
  • Cyclosporin analogs
    Patent number: 9493511
    Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: November 15, 2016
    Assignee: Allergan, Inc.
    Inventors: Catherine Simone Victoire Frydrych, William Robert Carling, Michael E. Garst, Michael E. Stern, Christopher S. Schaumburg
  • Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings
    Publication number: 20160289271
    Abstract: The present invention relates to novel cyclosporin analogs, processes for preparing them, pharmaceutical compositions containing them, and methods for using these analogs and the compositions containing them for the treatment of medical conditions, including but not limited to ocular conditions such as dry eye.
    Type: Application
    Filed: March 17, 2016
    Publication date: October 6, 2016
    Inventors: Simon N. Pettit, Andrew D. Jones, Catherine Simone V. Frydrych, Alex J. Thomas, Michael E. Garst
  • PHENYLCARBAMATE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS
    Publication number: 20160272581
    Abstract: The present invention relates to N-phenyl carbamate derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide 2 receptor.
    Type: Application
    Filed: November 20, 2014
    Publication date: September 22, 2016
    Applicant: Allergan, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, Michael E. Garst
  • Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators
    Patent number: 9428549
    Abstract: The present invention relates to derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide 2 receptor.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: August 30, 2016
    Assignee: Allegran, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS
    Publication number: 20160235711
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Application
    Filed: April 26, 2016
    Publication date: August 18, 2016
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Benzofuran-2-sulfonamides pyridine derivatives as chemokine receptor modulators
    Patent number: 9416120
    Abstract: The present invention relates to novel benzofuran-2-sulfonamide pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: August 16, 2016
    Assignee: Allergan, Inc.
    Inventors: Haiqing Yuan, Richard L. Beard, Michael E. Garst, Xiaoxia Liu, John E. Donello, Veena Viswanath
  • NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS
    Publication number: 20160228407
    Abstract: The present invention relates to novel bis-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Application
    Filed: September 8, 2015
    Publication date: August 11, 2016
    Inventors: Haiqing Yuan, Richard L. Beard, Michael E. Garst, Xiaoxia Liu, John E. Donello, Veena Viswanath
  • Antibiotic conjugates directly linked with steroid drugs
    Patent number: 9402912
    Abstract: The present invention describes novel single drug entities, formed by direct linkage of an antibiotic to a steroidal drug. Upon topical application to the eye, the conjugate would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs. The antibiotic is coupled directly to the steroid drug.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: August 2, 2016
    Assignee: Allergan, Inc.
    Inventors: Santosh C. Sinha, Ken Chow, Liming Wang, Michael E. Garst, Mayssa Attar, Brandon D. Swift
  • Cyclosporine A steroid conjugates
    Patent number: 9402913
    Abstract: The present invention describes Cyclosporine A/steroid hybrid analogs. These single drug entities are formed by connecting a steroid with Cyclosporine A. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: August 2, 2016
    Assignee: Allergan, Inc.
    Inventors: Santosh C. Sinha, Ken Chow, Liming Wang, Michael E. Garst, Mayssa Attar, Brandon D. Swift
  • CYCLOSPORIN DERIVATIVES WHEREIN THE MEBMT SIDECHAIN HAS BEEN CYCLIZED
    Publication number: 20160200767
    Abstract: The present invention relates to cyclosporin analogs that are potent inhibitors of cyclophilin D and have low immunosuppressive activity; processes for preparing them; pharmaceutical compositions containing them; and methods for using these analogs and compositions containing them for the treatment of medical conditions, including but not limited to ischemic conditions, such as ischemia-reperfusion (I/R) injury, including myocardial FR injury, cerebral I/R injury, and ocular or retinal I/R injury.
    Type: Application
    Filed: January 8, 2016
    Publication date: July 14, 2016
    Inventors: Simon N. Pettit, Andrew D. Jones, Catherine Simone V. Frydrych, Alex J. Thomas, Michael E. Garst
  • Bicyclic 1,3,4-oxadiazole derivatives as sphingosine-1-phosphate receptors' modulators
    Patent number: 9371296
    Abstract: The present invention relates to bicyclic 1,3,4-oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: June 21, 2016
    Assignee: Allergan, Inc.
    Inventors: Ling Li, Janet A. Takeuchi, Ken Chow, Wha Bin Im, Michael E. Garst